

α -Synuclein Oligomers and Clinical Implications for Parkinson Disease

Lorraine V. Kalia, MD, PhD,^{1,2} Suneil K. Kalia, MD, PhD,³ Pamela J. McLean, PhD,⁴
Andres M. Lozano, MD, PhD,³ and Anthony E. Lang, MD^{1,2}

Lewy bodies \rightleftarrows Parkinson's



α -synuclein oligomer toxicity



Impaired proteostasis (ER stress)
Membrane pore (intracellular calcium ion)
Impaired synapse function (GluR dysfunction)
Seeding (prion-like propagation)



α -synuclein as potential biomarkers
 α -synuclein as potential treatment targets